Aligos Therapeutics. has filed a patent for compounds of Formula (I) and their pharmaceutically acceptable salts, along with methods of synthesis and treatment of diseases using these compounds. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aligos Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240018126A1) discloses a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating coronavirus infections. The compound, as described in the claims, includes specific structural features such as R1 being cyano and Ring A1 being selected from various groups. Additionally, the compound may contain specific alkyl groups and nitrogen-containing heterocyclic rings, enhancing its potential therapeutic properties.

Furthermore, the patent application outlines methods for treating coronavirus, picornavirus, or norovirus infections using the disclosed compound. It also suggests combining the compound with other agents like ACE inhibitors, anticoagulants, and immunosuppressants for enhanced therapeutic effects. The application also describes a method for inhibiting coronavirus protease selectively over host proteases, highlighting the compound's specificity and potential as a targeted antiviral treatment. Overall, the patent application presents a novel compound and methods for combating viral infections, particularly coronaviruses, with potential implications for the development of antiviral therapies.

To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies